Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05152225
Other study ID # JENI2021IIA
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date January 1, 2022
Est. completion date June 30, 2022

Study information

Verified date December 2021
Source the Jeunes en Neuroradiologie Interventionnelle (JENI) research group
Contact Basile Kerleroux, MD-MSc
Phone +33145648222
Email basile.kerleroux@gmail.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The main objective of this study is to better estimate the rate of infectious intracranial aneurysms (IIA) in proved infective endocarditis (IE). It also aims to identify MRI markers capable of accurately predicting (or excluding) IIA; to assess the impact of the different MRI abnormalities on the outcome; to capture the real-world management of EI with neurological complications in comprehensive IE centers in France


Description:

Rationale: The incidence of Infective endocarditis (IE) in developed countries is approximately 3-15 per 100,000 pers-years. Discharge mortality remains 15-30% and therapeutic management suffers in many ways from the paucity of randomized studies.(1) Symptomatic neurological complications, which occur in 15 to 30% of patients, are the most frequent extra-cardiac complication of IE and are deemed to worsen the outcome of EI.(2,3) Among this overall neurological complications, Infectious Intracranial Aneurysms (IIA) are a relatively rare, yet probably underestimate, vessel wall injury caused by septic emboli, with potentially intracranial bleeding for the patients. Neuroimaging in the context of IE has gained wide acceptance and is encouraged in the current guidelines.(4,5) Nevertheless the benefit of early neuroimaging to optimize the initial therapeutic management remains debated.(6,7) While the appearance and the frequency of the various neurologic complications of EI are well known thanks to prospective cohort studies with systematic pre-therapeutic MRI(8-10), several clinically relevant questions are still unknow or approximate, including: 1/ What is the rate of IIA in proved EI. The current gold standard for the detection of these small and distally located aneurysms remains Digital Subtraction Angiography (DSA) and to our knowledge, there is no prospective unbiased cohort of IE with systematic DSA available in the literature. 2/ Are there MRI signs correlated with the presence of IIA on DSA? Several MRI markers such as sulcal SWI lesion or cerebral microbleeds (CMBs) with contrast enhancement look promising (10), but validation in unbiased prospective studies with systematic MRI and DSA is needed. 3/ What is the impact on the outcome of the different MRI abnormalities and of unruptured and ruptured IIA? As previously mentioned, the value of both MRI and DSA remain unclear to guide the acute therapeutic management of EI. A recent French survey highlighted differences between university Hospital in France in the management of IIA. Thus, the analysis of the current management of EI with neurological complications could also help at informing the design of future randomized trials. Questions: 1. Better estimate the rate of IIA in proved EI. 2. Identify MRI markers able to accurately predict (or exclude) IIA. 3. What is the impact of different MRI abnormalities on the outcome? 4. Capture the real-world management of EI with neurological complications in comprehensive EI centers in France Design and setting: Multi-site, prospective cohort study, with standardized imaging protocol, in academic centers where MRI and DSA are performed routinely in patients with EI. Ethics: As for all non-interventional studies of de-identified data, written informed consent will be waived and a commitment to compliance (Reference Methodology CPMR-4) will be filed to the French data protection authority (CNIL) prior to data centralization, in respect to the General Data Protection Regulation. Patients and proxies will be informed they could oppose the use of their data for research purposes.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 200
Est. completion date June 30, 2022
Est. primary completion date March 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - patients with left-sided active infective endocarditis (IE) satisfying modified Duke Criteria, - patients who underwent both digital subtraction angiography (DSA) and brainMRI (as part of routine care) - DSA protocol with 3D rotational for both carotids and one vertebral artery - MRI/MRA standardized protocol including at least: Diffusion, FLAIR, 3D SWI, 3DT1SE and post gadolinium 3DT1SE and 3D TOF (large field: from the vertex to the magnum foramen). Exclusion Criteria: - uncertain diagnosis of IE by infectious disease consultants - patients with chronic IE - MRI performed after the completion of Infectious intracranial aneurysms (IIA) treatment - MRI performed without contrast injection or complete protocol - More than 48-hours delay between performing MRI and DSA

Study Design


Intervention

Diagnostic Test:
Brain MRI
Brain MRI performed routinely in patients with EI
digital subtraction angiography (DSA)
Digital Subtraction Angiography (DSA) performed routinely in patients with EI

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
the Jeunes en Neuroradiologie Interventionnelle (JENI) research group Sainte Anne Hospital (Paris), University Hospital, Limoges

References & Publications (8)

Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, Barsic B, Lockhart PB, Gewitz MH, Levison ME, Bolger AF, Steckelberg JM, Baltimore RS, Fink AM, O'Gara P, Taubert KA; American Heart Association Committee on Rheumatic Fever, Endocarditi — View Citation

Carneiro TS, Awtry E, Dobrilovic N, Fagan MA, Kimmel S, Weinstein ZM, Cervantes-Arslanian AM. Neurological Complications of Endocarditis: A Multidisciplinary Review with Focus on Surgical Decision Making. Semin Neurol. 2019 Aug;39(4):495-506. doi: 10.1055 — View Citation

Cho SM, Rice C, Marquardt RJ, Zhang LQ, Khoury J, Thatikunta P, Buletko AB, Hardman J, Uchino K, Wisco D; Infective Endocarditis Strokes and Imaging Characteristics (IESIC) group. Magnetic Resonance Imaging Susceptibility-Weighted Imaging Lesion and Contr — View Citation

García-Cabrera E, Fernández-Hidalgo N, Almirante B, Ivanova-Georgieva R, Noureddine M, Plata A, Lomas JM, Gálvez-Acebal J, Hidalgo-Tenorio C, Ruíz-Morales J, Martínez-Marcos FJ, Reguera JM, de la Torre-Lima J, de Alarcón González A; Group for the Study of — View Citation

Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, Dulgheru R, El Khoury G, Erba PA, Iung B, Miro JM, Mulder BJ, Plonska-Gosciniak E, Price S, Roos-Hesselink J, Snygg-Martin U, Thuny F, Tornos Mas P, Vilacosta I, Zamorano JL; ESC S — View Citation

Iung B, Tubiana S, Klein I, Messika-Zeitoun D, Brochet E, Lepage L, Al-Attar N, Ruimy R, Leport C, Wolff M, Duval X; ECHO-IMAGE Study Group. Determinants of cerebral lesions in endocarditis on systematic cerebral magnetic resonance imaging: a prospective — View Citation

Migdady I, Rice CJ, Hassett C, Zhang LQ, Wisco D, Uchino K, Cho SM. MRI Presentation of Infectious Intracranial Aneurysms in Infective Endocarditis. Neurocrit Care. 2019 Jun;30(3):658-665. doi: 10.1007/s12028-018-0654-1. — View Citation

Snygg-Martin U, Gustafsson L, Rosengren L, Alsiö A, Ackerholm P, Andersson R, Olaison L. Cerebrovascular complications in patients with left-sided infective endocarditis are common: a prospective study using magnetic resonance imaging and neurochemical br — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The assess the occurrence of infectious intracranial aneurysms in proven infective endocarditis In all included cases, infectious intracranial aneurysms will be detected using cerebral Digital Subtraction Angiography (DSA), which remains the current gold standard for the detection of these small and distally located aneurysms. DSA protocol will include 2D and 3D rotational acquisitions on both carotid arteries and one vertebral artery. The number of infective endocarditis with infectious intracranial aneurysms will be referred to the total number of endocarditis to estimate the incidence of these cerebral anomalies. 3 months
Secondary To assess the diagnostic performance of MRI markers to detect infectious intracranial aneurysms Logistic regression and Linear Discriminant Analysis (LDA) methods will be used to identify the most relevant MRI signs to predict or exclude IIA (on DSA). 3 months
Secondary To assess the predictive performance of imaging markers on clinical outcome Logistic regression will be used to identify MRI and DSA sign associated with neurological worsening at follow-up. 2 years
Secondary To assess the rate of symptomatic intracranial haemorrhage following heart surgery In case of neurological deterioration after cardiac surgery, brain imaging (MRI or NCCT) will be performed to detect the occurrence or progression of cerebral haemorrhage. Logistic regression will be used to identify the MRI and DSA signs associated with this neurological complication. 6 months
See also
  Status Clinical Trial Phase
Terminated NCT00401960 - Daptomycin as an Adjuvant Agent in the Treatment of Enterococcal Native Valve Endocarditis. Phase 4
Terminated NCT00695903 - Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia Phase 2
Recruiting NCT05644990 - T2MR PCR Detection of ESKAPE Pathogens in Patients With Pyogenic Spondylodiscitis and Infective Endocarditis
Recruiting NCT04840225 - Anemia in Patients With Endocarditis
Completed NCT00524212 - How to Improve Diagnosis in Infective Endocarditis N/A
Completed NCT03048643 - Combining Opioid Addiction Treatment Services With CARe for Infectious Endocarditis N/A
Completed NCT00144885 - IMAGE-Endocarditis: Resonance Magnetic Imaging at the Acute Phase of Endocarditis N/A
Completed NCT03306225 - Characterization of Endocarditis to Streptococci and Impact of the CMI on the Future of the Patients
Active, not recruiting NCT05522764 - Predictors of Infective Endocarditis Among Patients Managed for Staphylococcus Aureus Bacteremia, Particularly Staphylococcus Aureus Bacteriuria, and Time to Blood Culture Positivity
Terminated NCT04222257 - Short-course Antibiotic Treatment in Gram-positive Cocci Infective Endocarditis Phase 4
Not yet recruiting NCT05613933 - Effectiveness of Antibiotic Prophylaxis of Infective Endocarditis for Invasive Dental Procedures in Patients With Prosthetic Heart Valves and/or History of Infective Endocarditis N/A
Recruiting NCT02979951 - Fosfomycin i.v. for Treatment of Severely Infected Patients
Active, not recruiting NCT06434012 - Barts Endocarditis Research Registry
Recruiting NCT06250985 - New Treatment of Cardiac Device Infections; Immediate Reimplantation After Removal of Infected System Phase 3